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Adult renal rhabdomyosarcoma is a rare subtype of renal sarcoma. We present a case of a renal mass treated with radical
nephrectomy that subsequently was shown to be renal rhabdomyosarcoma. We discuss the clinical presentation, imaging findings,
and histology for this case and review the available literature.
1. Introduction
Rhabdomyosarcomas of the kidney are a subtype of renal
sarcomas which are rarely reported in the literature and
arise from skeletal muscle progenitor cells. The histological
subtypes include embryonal, alveolar, and pleomorphic vari-
ants. Primary rhabdomyosarcomas in the adult population
are extremely rare. The majority of cases are seen in the
paediatric population and are commonest in the head
and neck region or urogenital tract. We report on a case
of primary embryonal rhabdomyosarcoma (ERMS) of the
kidney and review the available literature regarding diagnosis
and management.
2. Case Report
A 37-year-old woman, of Middle Eastern descent, was admit-
ted with a progressive six-month history of lethargy, weight
loss, right flank pain, and macroscopic haematuria. She was
passing thin “worms” of blood per urethra with abdominal
discomfort on voiding. No significant past medical history
was noted but she had a family history of liver carcinoma
(paternal aunt).
Examination revealed a well female with stable vital signs.
Respiratory and cardiovascular examination was unremark-
able. The abdomen was mildly distended with a palpable
ill-defined mass in the right upper quadrant found to be
distinct from the liver. Abnormal laboratory investigations
included a haemoglobin of 10.9 g/dL (11.5–16), haematocrit
0.322 (0.37–0.47), albumin of 30 g/L (35–51), C-reactive
protein of 38mg/L (0–5), and erythrocyte sedimentation rate
of 93mm/hr (<24). Serology revealed evidence of previous
Epstein-Barr virus infection. Urine analysis was positive for
blood (+++) and protein (+) with Escherichia coli cultured
on a midstream specimen.
Abdominal computed tomography (CT) demonstrated
a large heterogeneous mass measuring 16 centimetres and
replacing the right kidney (Figure 1). No definite local
invasion was noted but the tumour was pushing on the liver,
pancreas, and duodenum with no clear fat planes seen. CT
did not show any thrombus in the inferior vena cava (IVC)
above or below the tumour but it was reported that there
was venous invasion of the right ovarian vein. Two enlarged
lymph nodes were noted; however, there was no evidence of
bony deposits or bowel pathology. By CT staging, this was
at least T3, N1, and M0 with possible extension through the
perinephric fascia inferiorly making this T4 disease.
The patient underwent an elective open right radical
nephrectomy. At the time of surgery the tumour, originating
from the right kidney, was partially necrotic and adherent
to the liver and IVC. On further mobilisation of the tumour
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Figure 1: Cross-sectional computed tomography (CT) images showing a large heterogeneous mass replacing the right kidney.
it was noted to extend into the right ureter. Tumour was
identified to extend up to four centimetres above the bladder
and the ureter was mobilised to below palpable disease and
transfixed. The patient made an uneventful postoperative
recovery and was discharged a week later. Repeated CT
imaging at four months demonstrated no evidence of
recurrent or metastatic disease.
Histology confirmed that almost the entire kidney was
replaced by a multiloculated macrocystic and microcystic
tumour measuring 145 × 140 × 95mm. The tumour was
partly solid with areas that were pale and homogenous and
areas that were haemorrhagic. The ureter was filled with
haemorrhagic and solid tumour similar in appearance to the
solid haemorrhagic areas of the renal tumour. The tumour
was predominantly spindle cell neoplasm with areas of small
round blue cell tumour. Some cysts and epithelial compo-
nents were noted at the renal pelvis; however, these were not
thought to be part of the tumour and were thought to be
secondarily involved. There was abundant haemorrhage and
necrosis with an almost fibrinoid necrosis of vessels. The cells
had variably scant and indistinct cytoplasm in most of the
tumour although in some places eosinophilic cytoplasm was
noted. Nuclei were varied in size but were mostly round or
elongated.
Further immunohistochemical analysis revealed that the
tumour cells expressed both Myogenin and focally MyoD1.
There was strong staining in the cytoplasm for WT1 but
relative sparing of the nucleus. The tumour was CD99 and
PAX5 negative and lacked chromosomal changes associated
with synovial sarcoma.
3. Discussion
Sarcoma of the kidney is rare and accounts for 1% of all
primary renal malignancies [1, 2]. Of these, rhabdomyosar-
comas are the least frequently reported in the literature.
Adult cases are uncommon, arise mainly in large skeletal
muscles, and are usually of pleomorphic subtype [3].
The classification of rhabdomyosarcomas was first
described in 1958 into four histopathological subtypes: emb-
ryonal, botryoid-subtype of embryonal, alveolar, and pleo-
morphic [4, 5]. ERMS is the commonest subtype making up
to approximately 66% of all diagnosed cases and has the best
prognosis.
From the few cases in the literature it is diﬃcult to make
specific recommendations regarding diagnosis and manage-
ment. It is clear, however, that ERMS behaves aggressively
and presents late like other primary sarcomas. Median age
of presentation for renal sarcomas is 49 years and the average
size at diagnosis varies from 5.5 to 23 centimetres [6].
The diagnosis of primary renal sarcoma and specifically
ERMS is diﬃcult. The criteria for diagnosis of renal sarcomas
includes three components as defined by Grignon et al. [7].
Firstly there should be no evidence of sarcoma elsewhere to
exclude metastatic tumour from the diﬀerential. Secondly
a sarcomatoid RCC must be excluded and this is by
adequate sampling of the tumour to exclude an epithelial
component. Finally, extension of a retroperitoneal sarcoma
with secondary renal invasion can be excluded on histology.
Imaging characteristics of most sarcomas are indistin-
guishable from renal cell carcinoma and present as large non-
specific soft-tissue masses with poor contrast enhancement
[6]. It is therefore diﬃcult to oﬀer any predictive features for
ERMS on CT imaging. Thrombosis of the venous drainage
including the IVC as identified on imaging can be useful for
surgical planning [8]. In this case ovarian vein thrombosis
was reported with no extension into the IVC. It is interesting
to note that ureteric involvement was not picked up on CT.
The nature of the surgery made it impossible to confirm or
not if the ovarian vein was thrombosed or not and whether
therefore if the appearances seen on CT corresponded to
ureteric involvement instead. Whilst MRI was previously
thought to be the gold standard for renal tumour imaging,
several recent studies have shown comparable results with
CT [9].
The diagnosis of ERMS is a diﬃcult one to make on
clinical and imaging findings with several diﬀerentials to
consider. Histopathology after surgical resection is used to
confirm the diagnosis, although this in itself can be challeng-
ing. Myogenin and MyoD1, myogenic regulatory proteins
expressed early in skeletal muscle diﬀerentiation, are consid-
ered sensitive and specific markers for RMS and are more
specific than desmin and more sensitive than myoglobin
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[10]. Mutation of the WT1 gene is implicated in Wilm’s
tumours; however, in this case we found cytoplasmic staining
with nucleus sparing. This does not support a diagnosis of
Wilm’s tumour and the literature suggests that this correlates
with muscle diﬀerentiation and a diagnosis of RMS [11].
The literature is not suﬃcient to oﬀer specific recom-
mendations for treatment; however, it has been suggested
that the treatment should be as for ERMS in any other site.
The prognosis of primary renal sarcomas is poor with 90%
of cases demonstrating metastases at the time of diagnosis
[12]. The mainstay of treatment remains to be radical
nephrectomy.
Studies in children have demonstrated a use for pre-
operative chemotherapy and postoperative radiotherapy.
Evidence from the International RMS Study IV of 883
young patients (aged less than 20 years) showed improved
survival in ERMS with three-drug chemotherapy [13]. There
is much less data available for the use of chemotherapy and
radiotherapy in adult cases.
Several studies have suggested that RMS in adults has
a worse prognosis than in children. In contrast to the pae-
diatric population, no association has been shown between
survival and histological subtype in adults [14].
Data from a large series with a 20-year followup provides
some insight into treatment options and prognosis. A total
of 106 of 299 cases (35%) were rhabdomyosarcomas and
of these only 16 (15%) were diagnosed in adulthood. No
cases of primary renal disease were included. The data from
this series demonstrates that whilst overall prognosis for
genitourinary tumours across all ages is favourable (74% 5-
year survival rate), this does not appear to hold true for adult
disease. Only 1 of 6 adult genitourinary cases remained alive
and disease free at the 10-month followup [15]. Several other
studies have found the 5-year survival rate in adults to be
around 35% [16].
In summary, primary ERMS is a rare entity in adults
and there is little evidence to guide diagnosis and man-
agement in the literature. Whilst many suggest treatment
as per paediatric protocols, there is growing evidence that
the progression and prognosis of adult disease is unlike
paediatric disease. Radical nephrectomy is the gold standard
for treatment; however, there appears to be growing support
for the use of neoadjuvant chemotherapy in long-term failure
free survival.
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